- Investing.com
StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis. It also provides pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a stem cell gene therapy. The company was incorporated in 2006 and is headquartered in Ibaraki, Japan.
Metrics to compare | 4599 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4599PeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.0x | −5.6x | −0.6x | |
PEG Ratio | −0.89 | −0.07 | 0.00 | |
Price/Book | 2.8x | 4.7x | 2.6x | |
Price / LTM Sales | - | 31.6x | 3.4x | |
Upside (Analyst Target) | 132.6% | 39.4% | 39.6% | |
Fair Value Upside | Unlock | 9.8% | 5.2% | Unlock |